Huland H, Klöppel G, Feddersen I, Otto U, Brachmann W, Hubmann H, Kaufmann J, Knipper W, Lantzius-Beninga F, Huland E
Department of Urology, University of Hamburg, Federal Republic of Germany.
J Urol. 1990 Jul;144(1):68-71; discussion 71-2. doi: 10.1016/s0022-5347(17)39368-0.
In a prospective multicenter study we compared the value of various protocols of mitomycin C and doxorubicin instillation for the prevention of recurrent tumors in patients whose superficial bladder tumors (stages TA and T1) had been removed by transurethral resection. The 3-year and short-term instillation protocols were compared to each other and to a combination of 2 protocols. Evaluation after a mean followup of 28 months confirmed the value of cytostatic bladder instillation in preventing recurrence and progression of tumor in patients with superficial bladder carcinoma. There was no significant difference between the results of long-term and short-term prophylaxis; their combination achieved the best results. Doxorubicin and mitomycin yielded similar results; mitomycin was better tolerated.
在一项前瞻性多中心研究中,我们比较了多种丝裂霉素C和阿霉素膀胱灌注方案对于经尿道切除浅表性膀胱肿瘤(TA期和T1期)患者预防肿瘤复发的价值。将3年和短期灌注方案相互比较,并与两种方案联合使用的情况进行比较。平均随访28个月后的评估证实了细胞毒性膀胱灌注在预防浅表性膀胱癌患者肿瘤复发和进展方面的价值。长期和短期预防结果之间无显著差异;两者联合使用效果最佳。阿霉素和丝裂霉素产生了相似的结果;丝裂霉素耐受性更好。